Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Acute Coronary Syndrome (ACS)
4.5
$ 15.99
In stock
(463)
Product Description
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis
Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial - The Lancet
PDF) Safety and Effectiveness of Contemporary P2Y 12 Inhibitors in an East Asian Population With Acute Coronary Syndrome: A Nationwide Population‐Based Cohort Study
Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events
Effect of P2Y 12 inhibitors on frequencies of clinical outcomes in ACS
Comparison of the primary efficacy endpoint from studies which compared
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data
Role of More Potent Antiplatelet in ACS Management
JCM, Free Full-Text
Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Stroke Prevention
/cloudfront-us-east-1.images.arcpublishing.com/gray/XJHY63RI3ZLKLKPHB3F7HXUWSM.jpg)
